{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:22:36Z","timestamp":1793816556923,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T00:00:00Z","timestamp":1720310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022M3A9J1072296"],"award-info":[{"award-number":["2022M3A9J1072296"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003715","name":"Korea Research Institute of Bioscience and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117114","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T17:41:02Z","timestamp":1721842862000},"page":"117114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib"],"prefix":"10.1016","volume":"178","author":[{"given":"Min-Ji","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Ryoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-4192","authenticated-orcid":false,"given":"Yoon-Jee","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117114_bib1","unstructured":"US Food and Drug Administration, Guidance for industry: In vitro drug interaction studies - Cytochrome P450 enzyme and transporter mediated drug interactions, (2020). \u3008https:\/\/www.fda.gov\/media\/134582\/download\u3009 (accessed November 11, 2024)."},{"key":"10.1016\/j.biopha.2024.117114_bib2","unstructured":"US Food and Drug Administration, Guidance for industry: Clinical drug interaction studies - Cytochrome P450 enzyme- and transporter-mediated drug interactions, (2020). https:\/\/www.fda.gov\/media\/134581\/download (Accessed November 11, 2024).."},{"key":"10.1016\/j.biopha.2024.117114_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2024.117114_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.apsb.2016.07.013","article-title":"Renal drug transporters and their significance in drug\u2013drug interactions","volume":"6","author":"Yin","year":"2016","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.biopha.2024.117114_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.addr.2012.09.027","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"64","author":"Schinkel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.117114_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030855","article-title":"Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions","volume":"19","author":"Alam","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117114_bib7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/cpt.1360","article-title":"Clinical aspects of transporter-mediated drug\u2013drug interactions","volume":"105","author":"Gessner","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2024.117114_bib8","unstructured":"US FDA, Prescribinig Information: Bosutinib, (2023). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203341s025lbl.pdf (accessed November 11, 2024)."},{"key":"10.1016\/j.biopha.2024.117114_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117114_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","article-title":"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects","volume":"73","author":"Hsyu","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117114_bib11","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/jps.24378","article-title":"Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats","volume":"104","author":"Lee","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2024.117114_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s44211-022-00166-8","article-title":"Sensitive and valid assay for reliable evaluation of drug interactions mediated by human organic anion transporter 1 and 3 using 5-carboxyfluorescein","volume":"38","author":"Lee","year":"2022","journal-title":"Anal. Sci. Int. J. Jpn. Soc. Anal. Chem."},{"key":"10.1016\/j.biopha.2024.117114_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110504","article-title":"Strong inhibition of organic cation transporter 2 by flavonoids and attenuation effects on cisplatin-induced cytotoxicity","volume":"379","author":"Shin","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2024.117114_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/jpet.118.250225","article-title":"Suppression of canine ATP binding cassette ABCB1 in madin-darby canine kidney type II cells unmasks human ABCG2-mediated efflux of Olaparib","volume":"368","author":"Song","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.117114_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.107.123554","article-title":"Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family","volume":"322","author":"Chen","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.117114_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxlet.2024.02.011","article-title":"Roles of breast cancer resistance protein and organic anion transporting polypeptide 2B1 in gastrointestinal toxicity induced by SN-38 under inflammatory conditions","author":"Gulnaz","year":"2024","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.biopha.2024.117114_bib17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/jps.23005","article-title":"Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population","volume":"101","author":"Chae","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2024.117114_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.110886","article-title":"Pharmacokinetic interactions of niclosamide in rats: involvement of organic anion transporters 1 and 3 and organic cation transporter 2","volume":"390","author":"Kang","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2024.117114_bib19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.117114_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2014.03.005","article-title":"Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action","volume":"53","author":"Wang","year":"2014","journal-title":"Prog. Neuro\u00a0Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2024.117114_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/jpet.112.191577","article-title":"Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K","volume":"341","author":"Astorga","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.117114_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/mp800122b","article-title":"Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay","volume":"6","author":"Thiel-Demby","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.117114_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cpdd.396","article-title":"Absolute bioavailability of bosutinib in healthy subjects from an open-label, randomized, 2-period crossover study","volume":"7","author":"Hsyu","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.biopha.2024.117114_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/dmd.116.074450","article-title":"Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: prediction of drug\u2013drug and drug\u2013disease interactions","volume":"45","author":"Ono","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.117114_bib25","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1038\/s41598-021-85757-7","article-title":"Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.","volume":"11","author":"Abumiya","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117114_bib26","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics","volume":"164","author":"Yonezawa","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117114_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2133\/dmpk.20.379","article-title":"Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1","volume":"20","author":"Kimura","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2024.117114_bib28","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1124\/dmd.112.046508","article-title":"Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics","volume":"40","author":"Zamek-Gliszczynski","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.117114_bib29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40262-015-0270-6","article-title":"A comprehensive review of drug\u2013drug interactions with metformin","volume":"54","author":"Stage","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2024.117114_bib30","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-07-4793","article-title":"Interaction of Cisplatin with the human organic cation transporter 2","volume":"14","author":"Filipski","year":"2008","journal-title":"Clin. Cancer Res.\u00a0J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2024.117114_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40268-015-0120-x","article-title":"Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies","volume":"16","author":"Martin","year":"2016","journal-title":"Drugs R. D."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224009983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224009983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:57:34Z","timestamp":1777863454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224009983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":31,"alternative-id":["S0753332224009983"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117114","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117114"}}